The newest psychedelics company plans to focus on both ketamine- and psilocybin-assisted psychedelics R&D.
Industry heavyweight Compass Pathways launched the current rally in psychedelic stocks. But four other stocks have been outperforming CMPS.
Numinus commences psilocybin cultivation as part of its "ecosystem approach" to psychedelic drug therapy.
After a series of significant corporate appointments, Mind Cure is poised to advance its operations.
Mydecine's new patent application may lead to a way to derive the medicinal benefits of psilocybin at lower doses.
The mental healthcare industry is ripe for innovation. And companies like Mind Cure (CSE: MCUR), which recently completed its IPO, are set to lead the way.
Noted psychedelic drug expert, Hamilton Morris, is the latest addition to Mind Cure's advisory board.